Floatz logo

ETOPOSIDE

Double-Expressor Lymphoma

University of California, DavisSmall moleculePhase 2/3Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

71 Active assets in the Double-Expressor Lymphoma cohort.

Asset / SponsorPhaseRating
Axicabtagene Ciloleucel
Zhejiang Cancer Hospital
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Fludarabine
M.D. Anderson Cancer Center
Phase 4BB
Inno-206
Ruijin Hospital
Phase 3BB
PREDNISONE TABLETS
Ruijin Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →